CNSide Diagnostics Strikes Deal With Elevance Health To Offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay, Effective May 1, 2026

FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients

Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today

The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.

Watching Freenome; Traders Circulate Unconfirmed Analyst Comments Suggesting Carelon Healthcare Services (ELV) Just Updated Clinical Guideline Reimbursements To Include Freenome’s SimpleScreen

Can Cigna's Smart Coverage Help Close Health-Cost Gaps?

Cigna Healthcare is introducing Smart Coverage, a new benefit option that automatically links medical claims with supplemental benefits to provide eligible members up to $7,000 for covered health events. The program launches January 1, 2027, for mid-sized employers and addresses a significant affordability gap, with nearly 60% of Americans unprepared for health costs. The initiative is designed to increase enrollment in high-deductible plans and boost supplemental product participation.

8-K filing — CERENOME, INC. (PSTV)

Filed: 2026-08-14 AccNo: 0001193125-26-352346 Size: 668 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual